Pharmacoeconomic review report Riociguat (Adempas)
Riociguat (Adempas) is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1), as monotherapy or in combination with endothelin receptor antagonists (ERAs) in adult patients (≥ 18 years of age) with W...
| Autor principal: | |
|---|---|
| Autor Corporativo: | |
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
[Ottawa, Ontario] :
Canadian Agency for Drugs and Technologies in Health
2015.
|
| Colección: | Common drug review clinical review report.
|
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820268306719 |
